Chi Podcasts

CHI interviews Dr. Xavier Jacq, Head of Biology at MISSION Therapeutics regarding drugging deubiquitinase enzymes (DUBs), a rapidly emerging target class with the Ubiquitin Proteasome System (UPS). Discussion topics and questions include: 1. Tell us a little about MISSION and your current programs. 2. Why are these emerging as viable therapeutic targets? 3. What are drug discovery challenges in this space? What about inhibitor discovery, how challenging is this? 4. What might be challenges surrounding translating these compounds into the clinic? 5. What are some novel tools and technologies being developed to overcome some of these challenges? 6. You are giving a lecture at the 13th Annual Discovery on Target Conference, during the Targeting the Ubiquitin Proteasome System meeting. What do you hope to convey to attendees during your lecture this fall? 7. How have you seen this field evolve over the past few years, and where do you see it going in the future? For more information visit http://